Chemotherapy-free cure of hemoglobin disorders through base editing
通过碱基编辑无需化疗即可治愈血红蛋白疾病
基本信息
- 批准号:10754114
- 负责人:
- 金额:$ 80.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAffectAllogenicAmino AcidsAntigensAutologousAutologous TransplantationBiological AssayBone MarrowBone Marrow PurgingBypassCell TransplantationCellsClinicClinicalClinical TrialsClustered Regularly Interspaced Short Palindromic RepeatsCouplingCytokine ReceptorsDNA DamageDataDefectDevelopmentDiseaseDrug KineticsEndowmentEngineeringEngraftmentEpitopesErythroid CellsExtracellular DomainFLT3 geneFaceFetal HemoglobinFutureGene ModifiedGene TransferGeneticGenetic EngineeringGlobinGoalsGuide RNAHairHematological DiseaseHematologyHematopoiesisHematopoieticHematopoietic Stem Cell TransplantationHematopoietic stem cellsHemoglobinHemoglobinopathiesHomologous TransplantationHumanIL3RA geneImmuneImmunotherapyImmunotoxinsInfectionInfertilityInfusion proceduresInterventionLifeLigandsMalignant NeoplasmsMeasurableMedicalModelingModificationMonoclonal AntibodiesMucositisNatureNauseaParameter EstimationPathologicPatientsPharmaceutical PreparationsPhysiologicalPre-Clinical ModelProductionRadiation therapyRegimenRegulationResistanceRiskSickle Cell AnemiaSpecificitySystemTestingTherapeuticTherapeutic antibodiesTimeToxic effectTransfusionTranslationsTransplantationTreatment EfficacyValidationbase editingbeta Thalassemiacellular engineeringchemotherapychimeric antigen receptor T cellsclinical efficacyconditioningcurative treatmentsderepressionefficacy validationgene therapygenome-widegenotoxicityhemoglobin Binnovationmanufacturing processnew technologynovel strategiesnucleasepreservationprotein functionreceptorresearch clinical testingresponsescale upsicklingstem cell engraftmenttool
项目摘要
PROJECT SUMMARY
Sickle cell disease (SCD) and transfusion-dependent b-thalassemia (TDT) are severe, prevalent blood disorders
for which fetal hemoglobin (HbF) induction can bypass the fundamental hemoglobin defects and hematopoietic
stem/progenitor cell (HSPC) transplantation (HSCT) offers curative potential. Allogeneic and autologous trans-
plant approaches can succeed, nonetheless, the short- and long-term toxicities of genotoxic alkylating chemo-
therapy-based conditioning regimens remain a substantial barrier to the widespread application of curative HSCT
for SCD and TDT. Immunotherapies targeting HSPC antigens have been proposed as a safer conditioning strat-
egy, however the pharmacokinetics of these agents currently hamper their clinical efficacy. The long-term goal
of our proposal is to address this unmet medical need by developing an effective, novel strategy for the engraft-
ment and progressive enrichment of autologous gene modified HSPCs in SCD and TDT by coupling non-geno-
toxic immunotherapy-based myeloablation with epitope-engineering. Our central hypothesis is that precise
multiplexed base editing of HbF determinants and targeted epitopes within HSPCs can endow hematopoietic
lineages with both HbF induction capacity and selective resistance to monoclonal Abs or CAR-T cells without
affecting protein function or regulation (so-called stealth status). We have identified defined minimal amino-acid
changes within the extracellular domains (ECD) of the cytokine receptors KIT, FLT3 and IL3RA, each expressed
in long-term repopulating HSCs, that abrogate recognition by therapeutic Abs while preserving physiologic
responses to stimulation with their respective ligands. Here, we will capitalize on these results and further expand
the reach of these innovative genetic engineering tools with the objectives to i) generate “stealth” g-globin
derepressed HSPCs by multiplex CRISPR-Cas base-editing; ii) validate efficacy of this approach on suitable
pre-clinical models of b-hemoglobinopathy, and iii) further optimize and scale the manufacturing process for
production of efficiently and precisely engineered cellular products suitable to progress to the clinic. We aim: 1)
to optimize multiplex base editing approaches to simultaneously derepress HbF and engineer stealth HSPC
epitopes that will generate immunotherapy resistant hematopoietic stem cells capable of ameliorating sickling
and globin chain imbalance in SCD and TDT patient erythroid cells; 2) to maximize the engraftment of edited
HSCs by optimizing immunotherapy regimens to enrich multiplex edited HSPCs through modeling parameters
for therapeutic selection of edited HSPCs, and thereby obtaining proof-of-concept chemotherapy-free engraft-
ment and selection of edited patient HSPCs; and 3) to identify conditions that produce efficient on-target base
edits without measurable off-targets at clinical scale. This project will provide fundamental advancement of a
new chemotherapy-free gene therapy approach to HSCT for hemoglobinopathies that should additionally have
broad applicability to other hematopoietic disorders.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Daniel Evan Bauer其他文献
Daniel Evan Bauer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Daniel Evan Bauer', 18)}}的其他基金
Comprehensive characterization of variants underlying heart and blood diseases with CRISPR base editing
通过 CRISPR 碱基编辑全面表征心脏和血液疾病的变异
- 批准号:
10296877 - 财政年份:2021
- 资助金额:
$ 80.77万 - 项目类别:
Comprehensive characterization of variants underlying heart and blood diseases with CRISPR base editing
通过 CRISPR 碱基编辑全面表征心脏和血液疾病的变异
- 批准号:
10473734 - 财政年份:2021
- 资助金额:
$ 80.77万 - 项目类别:
Comprehensive characterization of variants underlying heart and blood diseases with CRISPR base editing
通过 CRISPR 碱基编辑全面表征心脏和血液疾病的变异
- 批准号:
10627940 - 财政年份:2021
- 资助金额:
$ 80.77万 - 项目类别:
Gene editing ELANE to understand and treat severe congenital neutropenia
基因编辑 ELANE 了解和治疗严重先天性中性粒细胞减少症
- 批准号:
10580862 - 财政年份:2020
- 资助金额:
$ 80.77万 - 项目类别:
Therapeutic BCL11A enhancer gene editing to induce fetal hemoglobin in β-hemoglobinopathy patients
治疗性 BCL11A 增强子基因编辑诱导 β 血红蛋白病患者胎儿血红蛋白
- 批准号:
10317505 - 财政年份:2020
- 资助金额:
$ 80.77万 - 项目类别:
Therapeutic BCL11A enhancer gene editing to induce fetal hemoglobin in β-hemoglobinopathy patients
治疗性 BCL11A 增强子基因编辑诱导 β 血红蛋白病患者胎儿血红蛋白
- 批准号:
10090251 - 财政年份:2020
- 资助金额:
$ 80.77万 - 项目类别:
Gene editing ELANE to understand and treat severe congenital neutropenia
基因编辑 ELANE 了解和治疗严重先天性中性粒细胞减少症
- 批准号:
10338097 - 财政年份:2020
- 资助金额:
$ 80.77万 - 项目类别:
Rectifying splicing mutations in blood disorders by gene editing
通过基因编辑纠正血液疾病中的剪接突变
- 批准号:
10531577 - 财政年份:2019
- 资助金额:
$ 80.77万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 80.77万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 80.77万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 80.77万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 80.77万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 80.77万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 80.77万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 80.77万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 80.77万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 80.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 80.77万 - 项目类别:
Studentship